Opioid Prescribing Practices and Health Outcomes among Patients with Alzheimer's Disease and Related Dementia

阿尔茨海默病和相关痴呆症患者的阿片类药物处方实践和健康结果

基本信息

批准号：
10693853
负责人：
Yu-Jung Wei
金额：
$ 53.86万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10693853
关键词：
Address Affect Alzheimer&apos s Disease Alzheimer&apos s disease patient Alzheimer&apos s disease related dementia Anticonvulsants Antidepressive Agents Caring Central Nervous System Central Nervous System Agents Central Nervous System Depressants Chronic Classification Clinical Clinical Trials Cognition Communities Community Surveys Complex Cytochrome P450 Data Data Set Dementia Diagnosis Dose Drug Kinetics Elderly Enzymes Goals Guidelines Health Hospitalization Impaired cognition Knowledge Link Literature Longitudinal Studies Longitudinal Surveys Medicare Medicare claim Medication Systems Memory Mental Depression Mental Health Metabolic Pathway Metabolism Nursing Assessment Nursing Homes Opioid Outcome Outcome Measure Overdose Pain Pain intensity Pain management Patient-Focused Outcomes Patients Pharmaceutical Preparations Pharmacotherapy Physical Function Population Population Study Probability Property Quality of Care Recommendation Reporting Research Retirement Role Safety Sampling Statistical Data Interpretation Surveys Time Vulnerable Populations Work chronic pain chronic pain management clinical effect cognitive function cognitive testing cohort comorbidity dementia risk fall injury falls follow-up high risk improved inhibitor longitudinal dataset neuropsychiatric symptom non-cancer chronic pain non-demented opioid therapy opioid use opioid use disorder pain symptom pharmacologic physical conditioning prescription opioid primary outcome safety outcomes secondary outcome

项目摘要

This study proposes a longitudinal study to assess the effects of opioid prescribing practices on outcomes of patients with Alzheimer’s disease and related dementia (ADRD). The research is responsive to priorities espoused by the National Plans to Address Alzheimer’s disease: Goal 2 Enhance Care Quality and Efficiency to address care needs of ADRD patients due to co-occurring chronic conditions. Chronic pain is common in ADRD, with 90% of affected patients relying on pharmacotherapy, such as opioids, to relieve painful symptoms. Use of prescription opioids in ADRD has doubled over the last decade; among users, over half used opioids chronically or concurrently with other central-nervous-system (CNS) depressant medications, contrary to what current pain guidelines suggest. These guidelines, however, adapt evidence primarily from younger populations or older adults with healthy cognition and whether they are suitable for ADRD patients remains unclear. To inform treatment decisions for pain management in ADRD, there is an urgent need for evidence on the clinical effects of existing opioid prescribing practices, considering outcomes aligned with treatment goals. For older adults who suffer from chronic pain, there is a strong need to understand if opioids improve or worsen cognition to help clarify inconclusive findings in the current literature. To fill these research gaps, this proposed study will leverage nationally representative longitudinal survey and assessment data that are linked to Medicare claims to study opioid prescribing practices on outcomes of ADRD patients residing in communities and nursing homes. Specifically, we will examine the associations between the continuation of chronic opioid therapy with outcomes in patients with ADRD and chronic non-cancer pain. We will also evaluate the extent to which concurrent use of opioids with CNS drugs is associated with outcomes in patients with ADRD receiving chronic opioid therapy. Furthermore, we will assess associations between opioid use and changes in cognitive function among non-demented older adults who had moderate or severe pain. We will consider a range of clinical outcomes, including pain intensity, physical and mental health, and safety outcomes, including fall-related injuries, hospitalizations, and opioid use disorder or overdose. Our study will provide empirical evidence on the effects of common opioid prescribing practices on health outcomes pertinent to patients with ADRD and elucidate the role of opioids on cognition in older adults with chronic pain. Because ADRD populations are rarely included in trials, our data will have great potential to further knowledge of the benefits and harms of opioid treatment and inform optimal use and safe opioid prescribing in patients with ADRD. The long-term goal of this line of research is to improve management of chronic pain in older adults, particularly those with cognitive impairment.

本研究提出了一项纵向研究，以评估阿片类药物处方实践对结果的影响该研究针对阿尔茨海默病和相关痴呆症 (ADRD) 患者的优先事项。解决阿尔茨海默病国家计划所支持的：目标 2 提高护理质量和效率解决 ADRD 患者因并发慢性疼痛而常见的护理需求。 ADRD，90% 受影响的患者依靠阿片类药物等药物治疗来缓解疼痛过去十年中，处方阿片类药物在 ADRD 中的使用量增加了一倍，超过一半；长期使用阿片类药物或与其他中枢神经系统 (CNS) 抑制剂同时使用，然而，与当前疼痛指南的建议相反，这些指南主要采用来自的证据。认知健康的年轻人或老年人以及他们是否适合 ADRD 患者目前尚不清楚，为了为 ADRD 疼痛管理的治疗决策提供信息，迫切需要现有阿片类药物处方实践的临床效果的证据，考虑到与以下结果一致的结果：对于患有慢性疼痛的老年人来说，非常需要了解阿片类药物是否有效。改善或延长认知，以帮助澄清当前文献中不确定的发现来填补这些研究。差距，这项拟议的研究将利用具有全国代表性的纵向调查和评估数据与医疗保险索赔相关，研究阿片类药物处方实践对居住在 ADRD 患者结果的影响具体来说，我们将研究持续性之间的关联。我们还将评估慢性阿片类药物治疗 ADRD 和慢性非癌症疼痛的效果。阿片类药物与中枢神经系统药物同时使用与患有以下疾病的患者的结局相关的程度 ADRD 接受长期阿片类药物治疗此外，我们将评估阿片类药物使用与 ADRD 之间的关联。患有中度或重度疼痛的非痴呆老年人的认知功能变化。考虑一系列临床结果，包括疼痛强度、身心健康以及安全性我们的研究将包括与跌倒相关的伤害、住院治疗和阿片类药物使用障碍或过量的结果。提供关于常见阿片类药物处方实践对相关健康结果影响的经验证据向 ADRD 患者提供帮助，并阐明阿片类药物对患有慢性疼痛的老年人认知的作用。 ADRD 人群很少被纳入试验中，我们的数据将具有巨大的潜力，可以进一步了解该人群阿片类药物最佳治疗的益处和危害，并为患有以下疾病的患者提供使用和安全阿片类药物处方的信息 ADRD 这一系列研究的长期目标是改善老年人慢性疼痛的管理，尤其是那些有认知障碍的人。

项目成果

期刊论文数量（3）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Short- and long-term safety of discontinuing chronic opioid therapy among older adults with Alzheimer's disease and related dementia.

患有阿尔茨海默病和相关痴呆症的老年人停止长期阿片类药物治疗的短期和长期安全性。

DOI：
发表时间：
2024-03-01
期刊：
影响因子：
6.7
作者：
Wei, Yu;Winterstein, Almut G;Schmidt, Siegfried;Fillingim, Roger B;Schmidt, Stephan;Daniels, Michael J;DeKosky, Steven T
通讯作者：
DeKosky, Steven T

Prevalence and trend of central nervous system-active medication polypharmacy among US commercially insured adults with vs without early-onset dementia: a multi-year cross-sectional study.

美国商业保险成人与非早发性痴呆患者中枢神经系统活性药物多重用药的患病率和趋势：一项多年横断面研究。

DOI：
发表时间：
2024-02-08
期刊：
影响因子：
0
作者：
Wei, Yu;Shrestha, Nistha;Chiang, ChienWei;DeKosky, Steven T
通讯作者：
DeKosky, Steven T

Pain intensity, physical function, and depressive symptoms associated with discontinuing long-term opioid therapy in older adults with Alzheimer's disease and related dementias.

患有阿尔茨海默病和相关痴呆症的老年人停止长期阿片类药物治疗后的疼痛强度、身体功能和抑郁症状。

DOI：
发表时间：
2024-02
期刊：
影响因子：
0
作者：
Wei, Yu;Winterstein, Almut G;Schmidt, Siegfried;Fillingim, Roger B;Daniels, Michael J;Solberg, Laurence;DeKosky, Steven T
通讯作者：
DeKosky, Steven T